ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

DPH Dechra Pharmaceuticals Plc

3,866.00
0.00 (0.00%)
20 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3,866.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

MILLENNIUM PARTNERS: Form 8.3 - Dechra Pharmaceuticals plc

16/01/2024 3:25pm

UK Regulatory


Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart


From Dec 2023 to Dec 2024

Click Here for more Dechra Pharmaceuticals Charts.
TIDMDPH 
 
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

 

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 
(a) Full name of discloser:              Millennium International Management 
                                         LP 
(b) Owner or controller of interests 
and short positions disclosed, if 
different from 1(a): The naming of 
nominee or vehicle companies is 
insufficient. For a trust, the 
trustee(s), settlor and beneficiaries 
must be named. 
(c) Name of offeror/offeree in           Dechra Pharmaceuticals plc 
relation to whose relevant securities 
this form relates: Use a separate 
form for each offeror/offeree 
(d) If an exempt fund manager 
connected with an offeror/offeree, 
state this and specify identity of 
offeror/offeree: 
(e) Date position held/dealing           15(th) January 2024 
undertaken: For an opening position 
disclosure, state the latest 
practicable date prior to the 
disclosure 
(f) In addition to the company in        No 
1(c) above, is the discloser making 
disclosures in respect of any other 
party to the offer? If it is a cash 
offer or possible cash offer, state 
"N/A" 
 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 
Class of relevant security:       1p ordinary (GB0009633180) 
                                  Interests          Short positions 
                                  Number     %       Number    % 
(1) Relevant securities owned 
and/or controlled:                -          -       -         - 
(2) Cash-settled derivatives:     1,842,274  1.617%  5,107     0.004% 
(3) Stock-settled derivatives 
(including options) and 
agreements to purchase/sell:      -          -       -         - 
 
 TOTAL:                           1,842,274  1.617%  5,107     0.004% 
 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 
Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant 
percentages: 
 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 
Class of relevant    Purchase/sale    Number of             Price per unit 
security                              securities            (GBP) 
 
 

(b) Cash-settled derivative transactions

 
                               Nature of dealing 
                               e.g. opening/closing 
                               a long/short 
                               position,                          Price 
Class of        Product        increasing/reducing    Number of   per 
relevant        description    a long/short           reference   unit 
security        e.g. CFD       position               securities  (GBP) 
                                 Increasing a long 
GB0009633180     Equity Swap      position             180,737     38.66 
                                 Increasing a long 
GB0009633180     Equity Swap      position             300,000     38.66 
                                 Increasing a long 
GB0009633180     Equity Swap      position             1,134       38.67 
                                 Increasing a long 
GB0009633180     Equity Swap      position             642         38.67 
                                 Increasing a long 
GB0009633180     Equity Swap      position             2,337       38.67 
                                 Increasing a long 
GB0009633180     Equity Swap      position             36          38.68 
                                 Reducing a long 
GB0009633180     Equity Swap      position             669         38.66 
 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 
Class of    Product        Writing,       Number of     Exercise    Type e.g.    Expiry    Option 
relevant    description    purchasing,    securities    price       American,    date      money 
security    e.g. call      selling,       to which      per         European               paid/ 
            option         varying        option        unit        etc.                   received 
                           etc.           relates                                          per 
                                                                                           unit 
 
 

(ii) Exercise

 
Class of        Product          Exercising/     Number of        Exercise 
relevant        description      exercised       securities       price per 
security        e.g. call        against                          unit 
                option 
 
 

(d) Other dealings (including subscribing for new securities)

 
Class of relevant       Nature of dealing      Details    Price per unit (if 
security                e.g. subscription,                applicable) 
                        conversion 
 
 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 
Details of any indemnity or option arrangement, or any agreement or 
understanding, formal or informal, relating to relevant securities which may 
be an inducement to deal or refrain from dealing entered into by the person 
making the disclosure and any party to the offer or any person acting in 
concert with a party to the offer: Irrevocable commitments and letters of 
intent should not be included. If there are no such agreements, arrangements 
or understandings, state "none" 
 
 NONE 
 

(b) Agreements, arrangements or understandings relating to options or derivatives

 
Details of any agreement, arrangement or understanding, formal or informal, 
between the person making the disclosure and any other person relating to: (i) 
the voting rights of any relevant securities under any option; or (ii) the 
voting rights or future acquisition or disposal of any relevant securities to 
which any derivative is referenced: If there are no such agreements, 
arrangements or understandings, state "none" 
 
 NONE 
 

(c) Attachments

 
Is a Supplemental Form 8 (Open Positions) attached?    NO 
 
 
Date of disclosure:    16(th) January 2024 
Contact name:          Stephen Glasper 
Telephone number:      +44 203 398 2166 
 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116740817/en/

 
    CONTACT: 

Millennium Partners, L.P.

 
    SOURCE: Millennium Partners, L.P. 
Copyright Business Wire 2024 
 

(END) Dow Jones Newswires

January 16, 2024 10:25 ET (15:25 GMT)

1 Year Dechra Pharmaceuticals Chart

1 Year Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock